1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Becton, Dickinson and Company

Becton, Dickinson and Company

BDX
Becton, Dickinson and CompanyUS flagNew York Stock Exchange
154.48
USD
-3.69
- -
55.97BMarket Cap
Becton, Dickinson and Company
BDX
(New York Stock Exchange)

Recent

price

154.48

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
30.4
34.29
37.52
41.27
43.69
50.77
58.69
55.23
61.86
64.05
57.62
66.13
66.21
67.67
69.64
75.93
75.11
Revenue per Share
5.62
5.75
5.69
6.63
6.13
3.43
4.59
4.7
0.62
4
2.75
6.92
5.93
4.97
5.88
5.83
4
Basic EPS, GAAP
7.04
7.35
8.58
8.81
9.02
8.54
12.03
11.65
11.09
12.34
12.69
16.07
9.24
10.44
13.1
11.93
13.47
Free Cash Flow per Basic Share
1.48
1.63
1.79
1.98
2.18
2.39
2.64
3.09
3.59
3.65
3.68
3.62
3.8
3.89
3.8
4.16
4.17
Dividend per Share
38.65
45.06
52.41
59.82
64.35
62.44
61.4
61.47
50.1
49.12
47.16
49.05
54.46
55.56
56.98
59.08
62.44
Book Value per Share
16.55
12.31
9.25
13.97
14.67
-38.31
-28.52
-2.33
-73.73
-63.99
-49
-44.92
-40.88
-33.78
-39.66
-36.94
-35.75
Tangible Book Value per Share
234
221
205
195
193
203
213
219
258
270
279
289
285
286
290
288
284
Basic Weighted Avg Shares
7,124
7,584
7,708
8,054
8,446
10,282
12,483
12,093
15,983
17,290
16,074
19,131
18,870
19,372
20,178
21,840
21,366
Sales/Revenue/Turnover
22.21
21.95
20.21
15.58
19.01
14.59
17.29
15.51
14.07
12.96
7.53
12.7
13.12
12.51
14.15
13.67
14.48
Operating Margin (%)
491
494
511
546
562
891
1,114
1,088
1,978
2,253
2,115
2,230
2,229
2,288
2,286
2,462
2,465
Depreciation Expense
1,318
1,271
1,170
1,293
1,185
695
976
1,100
311
1,233
874
2,092
1,779
1,484
1,705
1,678
1,138
Net Income, GAAP
28.84
25.77
24.66
20.26
22.14
5.95
9.03
- -
73.49
- -
14.98
5.2
8.3
7.94
14.96
10.79
14.16
Effective Tax Rate (%)
18.49
16.76
15.18
16.05
14.03
6.76
7.82
9.1
1.95
7.13
5.44
10.94
9.43
7.66
8.45
7.68
5.33
Profit Margin (%)
2,834
2,845
3,344
3,743
3,896
1,278
1,967
15,291
195
1,009
3,133
2,212
330
2,035
1,512
942
-495
Working Capital
1,495
2,485
3,761
3,763
3,768
11,370
10,550
18,667
18,894
18,081
17,224
17,110
13,886
14,738
17,940
17,621
14,706
LT Debt
5,435
4,828
4,136
5,042
5,053
7,165
7,634
12,948
20,994
21,082
23,765
23,677
25,282
25,797
25,889
25,390
24,132
Total Equity
15.86
16.84
14.84
11.54
13.83
9.71
9.95
- -
1.59
- -
2.5
5.53
5.47
5.36
5.53
5.86
6.18
Return on Invested Capital (%)
13.06
11.38
9.21
9.18
8.05
4.99
5.31
- -
1.49
- -
4.15
8.07
6.76
6
6.3
6.11
4.69
Return on Capital (%)
15.37
13.36
11.29
11.52
9.83
5.54
7.59
7.77
1.2
8.25
5.81
14.64
11.37
9.06
10.52
10.02
6.64
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
ST Debt
1,560
2,623
2,573
LT Borrowings
17,621
16,916
14,706
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
285
285
276
Market Capitalization
42,378
43,739
44,726

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
Total Current Assets
9,255
9,189
8,012
Cash, Cash Equivalents & STI
649
751
816
Accounts Receivable, Net
2,994
2,508
2,205
Inventories
3,894
4,085
3,357
Total Current Liabilities
8,313
8,761
8,507
Payables & Accruals
6,752
6,138
5,934
ST Debt
1,560
2,623
2,573
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.83%
1.38%
-1.93%
Free Cash Flow
10.14%
3.78%
-9.64%
Net Income, GAAP
36.99%
24.23%
-1.58%
Sales/Revenue/Turnover
8.43%
6.54%
8.24%
Total Cash Common Dividend
9.65%
5.43%
8.73%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,706
5,045
4,990
5,437
20,178
2025
5,168
4,480
5,509
5,891
21,840
2026
5,252
4,714
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.97
1.85
1.68
1.38
5.88
2025
1.05
1.07
2
- -
5.83
2026
1.34
-1.11
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.95
0.95
0.95
0.95
3.8
2025
1.04
1.04
1.04
- -
4.16
2026
1.05
1.03
- -
- -
- -
Similar Companies
Jin Medical International Ltd. (ZJYL)
Sanara MedTech Inc. (SMTI)
Pixium Vision S.A. (ALPIX.PA)
Sartorius Stedim Biotech S.A. (DIM.PA)
Dentium Co. Ltd. (145720.KS)
SKAN Group AG (SKAN.SW)
Business
Becton, Dickinson and Company (BDX) manufactures and distributes medical devices, instrument systems, and reagents worldwide. The company develops, produces, and sells a broad portfolio of products including syringes, catheters, infusion therapy devices, and diagnostic systems; safety-engineered sharps and vascular access products; BD Alaris infusion pumps and Pyxis medication management solutions; BD FACSAria flow cytometers and Rhapsody single-cell analysis platforms; and laboratory automation systems such as BD Kiestra and BD Synapsys informatics. BD operates in three main segments—BD Medical, BD Life Sciences, and BD Interventional—serving healthcare facilities, laboratories, pharmaceutical companies, and research institutions across North America, Europe, Asia-Pacific, and emerging markets. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD maintains a global presence with manufacturing facilities in more than 50 countries. In recent developments, BD completed the spin-off of its Biosciences solution business into a standalone entity in early 2025, enabling focused growth in high-margin diagnostics and cell analysis; the company also expanded its partnership with GE HealthCare for integrated medication management technologies and launched new Alaris iPC infusion pump features to enhance cybersecurity and interoperability.

Company News

APIChatGPT

  • fool.com

    My Top Dividend Growth Stock to Buy in July and Hold Forever

  • prnewswire.com

    BD to Announce Financial Results for its Third Quarter of Fiscal 2026

  • zacks.com

    Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?

  • fool.com

    Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

  • fool.com

    5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years

  • seekingalpha.com

    Becton, Dickinson - Stable Undervaluation In 1Q26, Upside Is There

  • prnewswire.com

    BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System

  • fool.com

    5 Dividend Stocks to Buy and Hold Forever

  • fool.com

    3 Excellent Dividend Stocks to Buy on the Dip

  • finbold.com

    Rep Thomas Kean just filed 4 new congressional stock trades

  • forbes.com

    The Healthcare M&A Wave

  • zacks.com

    Here's Why You Should Retain BDX Stock in Your Portfolio Now

  • seekingalpha.com

    Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

  • benzinga.com

    Jim Cramer: Buy Becton Dickinson, This Tech Stock Has Too High Valuation

  • fool.com

    Best 3 Blue Chip Stocks to Buy After a Market Pullback -- Including Microsoft (MSFT) Stock

  • zacks.com

    BD Launches Elyra Thulium Fiber Laser System for Kidney Stone Care

  • prnewswire.com

    BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System

  • prnewswire.com

    Peter Menziuso Named EVP and President, BD Interventional

  • youtube.com

    AI, Robotics Key to Transforming Health Care: BD CEO

  • seekingalpha.com

    Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript